Breast Diseases Clinical Trial
Official title:
Supplemental Screening for Breast Cancer With Abbreviated Breast MR for Black Women With Increased Breast Density
NCT number | NCT04854304 |
Other study ID # | 844978 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 23, 2021 |
Est. completion date | July 13, 2025 |
500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clinically asymptomatic- no palpable masses, focal thickening or clinically significant discharge. Investigators will identify these patients EPIC database utilizing the date of their last mammogram. Interested patients may contact our research coordinators by the phone number provided in the recruitment materials. The study recruitment information will also be shared with referring physicians. Physicians may also directly refer patients to the study.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | July 13, 2025 |
Est. primary completion date | July 13, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 40 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. African American female 2. Negative DBT examination within eleven months prior to recruitment 3. Heterogeneoulsy and Extremely breast densities 4. Clinically asymptomatic- no palpable masses or focal thickening, etc. Exclusion Criteria: 1. Patients who are pregnant and lactating 2. Patient who have not had a mammogram (DBT) in the past 11months 3. Patients who are unwilling or unable to provide written informed consent 4. Patients symptomatic for breast disease (e.g. experiencing discharge, lumps, ect.) 5. Recent breast surgery in the past 2 years including breast enhancements (e.g. implants or injections) 6. Patients who are unable to received an MRI with Gadolinium contrast 7. Patients who have not had an MRI of the breast with the past year |
Country | Name | City | State |
---|---|---|---|
United States | UPENN | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Abramson Cancer Center at Penn Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Breast cancer detection and false negative rates of supplemental screening with AB-MR | The cancer detection and false negative rate (per 1000 women screened) of supplemental screening with AB-MR in this population will be measured as well as the stage, grade and subtype of detected and non-detected breast cancers. | Through the completion of study, an average of 4 year | |
Primary | Additional screening outcomes | The rates of false positive exams prompting biopsy and short term follow-up recommendations after AB-MR will be evaluated. | Through the completion of study, an average of 4 year | |
Secondary | The screening outcomes of AB-MR in this population of Black women will be compared to a similar population of Caucasian women undergoing AB-MR. | The cancer detection, false negative and false positive rates as well as stage and subtypes of cancers will be compared to a similar population of Caucasian women screened with AB-MR | Through the completion of study, an average of 4 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01678170 -
Clinical Application of Breast Blood-oxygen Functional Imaging Technology
|
N/A | |
Completed |
NCT00039780 -
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
|
Phase 3 | |
Completed |
NCT02909452 -
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04535466 -
Diagnosis Predictive Modle for Dense Density Breast Tissue Based on Radiomics
|
||
Recruiting |
NCT01917279 -
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
|
Phase 3 | |
Recruiting |
NCT01427400 -
The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction
|
Phase 4 | |
Completed |
NCT05665894 -
Vacuum-Assisted Evacuation (VAE) Of Symptomatic and/or Voluminous Breast Haematomas Following Surgeries And Percutaneous Procedures: a Retrospective Analysis
|
||
Not yet recruiting |
NCT04088110 -
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
|
Phase 2 | |
Terminated |
NCT02997540 -
Effect of Body Position and Probe Position on the Localization of Breast Mass
|
||
Terminated |
NCT01140776 -
Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy
|
N/A | |
Recruiting |
NCT04911101 -
Performance Indicators and Patient Experience in 7G and 10G Vacuum-assisted Excision of Probably Benign Breast Lesions
|
N/A | |
Completed |
NCT04554316 -
Aesthetic Effect of Steri-Strip Orientation on Healing and Scar Appearance in Breast Surgery
|
N/A | |
Suspended |
NCT04151368 -
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
|
N/A | |
Completed |
NCT03743259 -
To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions
|
Phase 2 | |
Recruiting |
NCT04605575 -
Pyrotinib Plus Vinorelbine in Participants With HER2-positive Previously Treated Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
Completed |
NCT02452333 -
Oncoplastic Approach to Excisional Breast Biopsies
|
N/A | |
Terminated |
NCT01372215 -
Multi-Compression Spot Mammography
|
N/A | |
Completed |
NCT00299039 -
T3AI-Pain After Breast Surgery
|
Phase 3 | |
Active, not recruiting |
NCT05441943 -
Lymphaticovenous Anastomosis as Treatment for Lymphedema
|
N/A |